Breakdown | |||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|
Income Statement | Total Revenue | ||
0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | 0.00 | 0.00 | 0.00 | EBIT |
-55.19M | -62.64M | -2.68M | -1.09M | EBITDA |
-55.19M | -60.56M | -27.33M | 8.42M | Net Income Common Stockholders |
-45.39M | -60.36M | 3.55M | 8.42M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||
176.50M | 99.81M | 13.79K | 4.72M | Total Assets |
179.53M | 100.84M | 141.51M | 4.72M | Total Debt |
0.00 | 0.00 | 355.60K | 0.00 | Net Debt |
-176.50M | -99.81M | 341.81K | -4.72M | Total Liabilities |
19.51M | 21.29M | 14.82M | 39.00K | Stockholders Equity |
146.81M | 59.33M | -32.06M | 4.68M |
Cash Flow | Free Cash Flow | ||
-28.15M | -23.05M | -13.07M | -1.10M | Operating Cash Flow |
-28.08M | -15.05M | -1.07M | -1.10M | Investing Cash Flow |
-5.08M | -8.00M | -12.00M | -139.38M | Financing Cash Flow |
109.84M | 121.29M | 355.60K | 141.21M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $5.31B | 3.33 | -39.82% | 2.92% | 17.95% | 1.84% | |
49 Neutral | $86.93M | ― | -58.80% | ― | -100.00% | -24.28% | |
44 Neutral | $94.63M | ― | -31.39% | ― | ― | 15.09% | |
38 Underperform | $98.46M | ― | -44.03% | ― | ― | 86.65% | |
35 Underperform | $92.76M | ― | -70.13% | ― | ― | 1.27% | |
34 Underperform | $77.72M | ― | -47.99% | ― | -71.01% | -14.04% | |
30 Underperform | $80.88M | ― | -9999.00% | ― | ― | 27.65% |
On February 24, 2025, Zura Bio announced its participation in the Leerink Partners Global Healthcare Conference scheduled for March 11, 2025. The company’s senior leadership will engage in a fireside chat and host investor meetings, reflecting its proactive approach to engaging with stakeholders and potentially enhancing its market visibility.